Roberts Glore & CO Inc Neurocrine Biosciences Inc Transaction History
Roberts Glore & CO Inc
- $328 Million
- Q2 2024
A detailed history of Roberts Glore & CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Roberts Glore & CO Inc holds 1,492 shares of NBIX stock, worth $179,293. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,492
Previous 1,492
-0.0%
Holding current value
$179,293
Previous $205,000
-0.0%
% of portfolio
0.06%
Previous 0.06%
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.71 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.21 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$554 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$297 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$284 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...